Related Experiment Videos
Risk reduction following regression of cardiac hypertrophy
1Department of Medicine, University of Bonn, Venusberg, FRG.
Insights
Reducing left ventricular hypertrophy in essential hypertension is crucial. Certain antihypertensive drugs effectively reduce hypertrophy and associated arrhythmias, potentially lowering cardiovascular risk.
Area of Science:
- Cardiology
- Hypertension Research
- Pharmacology
Background:
- Cardiac hypertrophy in essential hypertension is an independent risk factor for heart failure, coronary heart disease, and sudden cardiac death.
- Left ventricular hypertrophy (LVH) reduction presents a significant challenge in antihypertensive treatment.
Purpose of the Study:
- To evaluate the impact of different antihypertensive treatments on left ventricular hypertrophy.
- To assess the effects of LVH reduction on cardiac function and ventricular arrhythmias.
Main Methods:
- Review of studies investigating antihypertensive agents (sympatholytics, calcium entry blockers, ACE inhibitors, vasodilators, diuretics) and their effect on LVH.
- Analysis of data on cardiac pump function (systolic and diastolic) in patients with reduced LVH.
- Examination of the relationship between LVH, ventricular arrhythmias, and cardiovascular outcomes with specific drug classes.
Main Results:
- Sympatholytic agents, calcium entry blockers, and angiotensin converting enzyme inhibitors reduce LVH; vasodilators and diuretics do not, despite effective blood pressure control.
- Reduction of LVH does not impair systolic or diastolic cardiac function.
- LVH reduction, particularly with beta-blockers, calcium entry blockers, or ACE inhibitors, is associated with decreased ventricular arrhythmias.
Conclusions:
- Specific antihypertensive medications effectively reduce left ventricular hypertrophy and associated arrhythmias.
- While not definitively proven, clinical evidence suggests that reducing LVH may decrease cardiovascular risk in hypertensive patients.
Abstract:
Cardiac hypertrophy in essential hypertension is documented to be an independent risk factor for congestive heart failure, coronary heart disease and cardiac sudden death. Reduction of left ventricular hypertrophy therefore emerged as a new challenge of antihypertensive treatment. Sympatholytic agents, calcium entry blockers, and angiotensin converting enzyme inhibitors have been found to reduce left ventricular hypertrophy, whereas vasodilators (and most likely also diuretics) are unable to reduce left ventricular mass despite good control of arterial hypertension. Several studies indicated that reduction of left ventricular hypertrophy is not detrimental to cardiac pump function: systolic and diastolic function were found to be maintained at rest and during exposure to increased pressure load. In hypertensive patients with left ventricular hypertrophy ventricular arrhythmias have been reported to be increased and to be the pathophysiological link for the increased risk of cardiac sudden death. Reduction of cardiac hypertrophy was found to be accompanied by a reduction of prevalence and severity of ventricular arrhythmias if treated with betablockers, calcium entry blockers or converting enzyme inhibitors. Whether reduction of cardiac hypertrophy indeed decreases the cardiovascular risk attributed to left ventricular hypertrophy is unknown at present, although clinical studies support such a viewpoint.